Drug
Tiotropium Bromide
Tiotropium Bromide: highest development phase Post-Market, developed by Boehringer Ingelheim, Orion Corporation. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Boehringer Ingelheim, Orion Corporation
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tiotropium bromide NCT00563381 | Post-Market | Pulmonary Disease, Chronic Obstructive |
| Tiotropium bromide NCT01122680 | Phase 2 | Asthma |
| Tiotropium Bromide Monohydrate NCT03400241 | Phase 1 | Healthy Subjects |
Latest
No recent events.
Follow Tiotropium Bromide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.